

Company name: KYORIN Holdings, Inc.  
Representative: Minoru Hogawa  
Representative Director, President  
(Securities Code: 4569, TSE 1st Sec.)

## **KYORIN Pharmaceutical and PeptiDream Reach Agreement for Peptide Discovery Collaboration.**

**TOKYO, Japan (November 5, 2015)** —The KYORIN Holdings, Inc. subsidiary, KYORIN Pharmaceutical Co., Ltd. (Head office: Tokyo Japan, President: Mitsutomo Miyashita, “Kyorin Pharmaceutical”) has announced a multi-target discovery and optimization collaboration with PeptiDream Inc. (Head Office: Tokyo Japan, President: Kiichi Kubota, “PeptiDream”).

Under the agreement, Kyorin Pharmaceutical will use PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) technology to generate macrocyclic/constrained peptides against targets of interest and to develop and commercialize all therapeutic peptides. In addition to the current development of low-molecular drugs, Kyorin Pharmaceutical will use PeptiDream’s innovative PDPS technology as a next-generation drug discovery approach to identify new compounds against targets in the disease areas of interest to Kyorin Pharmaceutical.

Kyorin Pharmaceutical will provide PeptiDream with an undisclosed upfront payment and milestone payments, as well as royalties according to a fixed ratio of sales of any products after commercialization that arise from the collaboration.

With its long-term vision “HOPE 100,” the Kyorin Pharmaceutical Group actively promotes R&D on the basis of the recognition that the discovery, development and provision of new drugs contributing to the health of people worldwide enhance the significance of the existence of a pharmaceutical company and lead to its continued growth. Kyorin Pharmaceutical continues to develop new drugs with a high degree of originality, not only using its own technology, but through enhanced collaborations with academia, venture companies, etc.

The companies expect the impact of the conclusion of this agreement on consolidated financial forecasts for the fiscal year ending March 31 2016 to be negligible.

End

[About PeptiDream Inc.]

Company name : PeptiDream Inc.

Head Office : KOL Building 4th floor, Komaba Research Campus, The University of Tokyo, 4-6-1  
Komaba, Meguro-ku, Tokyo

President : Kiichi Kubota

Established : July 2006

Capital : JPY2,743,872,000 (as of December 31, 2014)

Business lineup : Discovery, development and R&D of drugs using its proprietary Peptide Discovery  
Platform System (PDPS) to generate macrocyclic/constrained peptides